CRWD -31.57AMD -14.48AVGO -59.47TVE.TO 0.45BHP -2.54BBD.B.TO -0.79OWL 0.695
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.71
+0.37 (1.46%)
as of Jun 4, 2026, 6:38:50 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
PAST TOP PICK

Pfizer Inc(PFE)

Oct 15, 2003
(A top pick Sep 19/03. Down 1.8%.) Still likes the area and this is the premier company.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$30.60

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 03, 2003
Drug industry has been experiencing difficulties over the past 12 months. Thinks the industry has growth going forward.
Photo of Ray SteeleRay SteeleUnlock Rating
$30.78

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 29, 2003
Viagra is about to have its first major competitor, which could be a significant threat. Pharmaceutical industry suffers from trademark litigations.
Photo of David BaskinDavid BaskinUnlock Rating
$30.89

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 26, 2003
One of the best pharmaceutical companies but have concerns about pharmaceutical companies because of a lot of pressure on prices. The pipeline, two to three years out looks pretty thin.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$30.56

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Sep 25, 2003
Has a strong pipeline and strong products. They've taken some write-offs of Pharmacia from their balance sheet. Model price is $36/37.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$30.53

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 23, 2003
Investors are worried about generic drugs coming in. Likes the sector and likes the valuation.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$31.60

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 19, 2003
The big pharmas are trading at low multiples. Trading at 15 X 2004 earnings. Great value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$31.45

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2003
One of the premier drug companies in the world. Good dividend. Generates a lot of cash. Have 20 new drugs that they'll be releasing. Good price.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$32.05

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 04, 2003
This stock and Merk are not acting well. Some talk of downward earning revisions. Seeing pressures on high drug prices.
Photo of Ross HealyRoss HealyUnlock Rating
$30.60

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Sep 03, 2003
Has a big portfolio of drugs. Buying under $30. Trading at a significant discount to the market. Profit margins are shrinking because of government pressures because of deficits. Competition from generic drugs.
Photo of Brad WillockBrad Willock
Owned
Unlock Rating
$30.88

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 29, 2003
In a decline in the charts.
Photo of David ChapmanDavid Chapman
No
Unlock Rating
$29.92

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 27, 2003
Likes the company at these levels. Their recent merger will create growth. There should be 13/14% growth in earnings over the next couple of years.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$29.91

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2003
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.The strongest of the drug companies and the deepest pipeline.A good price to buy out for the long-term.
Photo of Matt BaraschMatt BaraschUnlock Rating
$29.55

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 18, 2003
(A top pick July 23/03.Down 4 «%.)Drug companies , stocks have dropped because they think of concerns on drug pricing.Longer-term demographically Phizer is very well-positioned.It represents great long-term value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$31.47

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 12, 2003
Model price is around $29.Prefers Merk.Too expensive.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$32.87

Stock price when the opinion was issued

$25.71

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 751 to 765 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PANW -3.74$276.69
GS 51.85$1092.87
AAPL 1.59$311.85
BUG -0.365$36.405
ABBV 6.495$223.625

Today's Top Picks

CRWD -31.57$716.04
AMD -14.48$528.04
AVGO -59.47$419.76
TVE.TO 0.45$14.02
BHP -2.54$88.31

Popular Articles

Latest Sell Signals

AVGO -59.47$419.76
LDOS 1.85$126.2
CME 0$
ULTA -8.555$462.655
MRVL 11.85$313.5

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Bryn Talkington

Requisite Capital Management

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica